BiotechTube
Santa Ana Bio

Santa Ana Bio

San Diego, United States· Est.
santaanabio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $222M

Overview

Santa Ana Bio is a San Diego-based biotech focused on precision therapeutics for autoimmune and inflammatory disorders. The company's core strategy is built on a proprietary multi-omics platform that integrates genomic, transcriptomic, and proteomic data to identify specific molecular drivers of disease, enabling the design of highly targeted biologics. Its pipeline features three core programs: a bispecific for mast cell depletion (SAB01), a CD40-targeted glucocorticoid ADC (SAB05), and a portfolio of multi-specifics for GI diseases (SAB06), all in preclinical development. Santa Ana Bio aims to move beyond broad-spectrum immunosuppression by creating therapies with meticulous accuracy and improved safety profiles.

Autoimmune DiseasesInflammatory Diseases

Technology Platform

A precision multi-omics platform that integrates genomic, transcriptomic, and proteomic data to decode disease biology and identify specific molecular drivers for the design of targeted biologics.

Funding History

3
Total raised:$222M
Series A$168M
Series A$50M
Seed$4M

Opportunities

The large and growing global prevalence of autoimmune diseases presents a substantial market.
The company's focus on precision targeting and novel modalities like targeted steroid ADCs and mast-cell-specific bispecifics addresses clear unmet needs for safer, more effective therapies.
Success with its platform could enable a sustainable pipeline of differentiated biologics.

Risk Factors

High preclinical and translational risk associated with novel, complex biologic modalities.
As a private, pre-revenue company, it faces significant financial risk and dependency on external funding.
Intense competition in the immunology space from larger, well-resourced companies could challenge market entry.

Competitive Landscape

The autoimmune and inflammatory disease therapeutic area is highly competitive, dominated by large pharma and numerous biotechs with advanced pipelines. Santa Ana Bio competes by focusing on precision targeting and novel engineering (bispecifics, ADCs, multi-specifics) to differentiate from broad immunosuppressants and single-mechanism biologics.

More companies in Biologics / Biosimilars →More companies in United States →